Business
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients with MDS or AML presented at the 2022 Transplantation & Cellular Therapy (TCT) Annual MeetingClinical data from the Phase 1/ 2 study of JSP191 as single agent conditioning in SCID patients presented at the 2022 Clinical Immunology Society (CIS) Annual MeetingJasper to initiate a new study of JSP191 as a second-line therapy for patients with lower-risk MDS later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic stem cell therapies, today announced first quarter 2022 financial results and provided a corporate update. “We had a productive first quarter advancing our clinical programs for JSP191, our anti-CD117 monoclonal antibody, including a successful meeting with the FDA to advance JSP191 into a registrational study for AML and MDS patients, and positive data readouts presented at both the Transplantation & Cellular Therapy (“TCT”) and Clinical Immunology Society (“CIS”) annual meetings,” said Ronald Martell, Jasper’s President and CEO. “The updated clinical data presented at the TCT meeting demonstrated that conditioning with a single dose of JSP191 on top of a standard course of non-myeloablative (“NMA”) conditioning in patients with myelodysplastic syndromes (“MDS”) or acute myeloid leukemia (“AML”) can be well-tolerated, safe and lead to successful engraftment with neutrophil recovery and full donor myeloid chimerism. Moreover, 20 out of 24 patients were free from morphologic relapse or disease progression at their last follow-up. There is a compelling need for new conditioning regimens with minimal toxicities and enhanced disease control in the growing population of older patients with AML or MDS undergoing transplant. Based on the encouraging data presented at TCT and the positive feedback from the FDA, we now have a path forward to initiate a registrational study of JSP191 in older patients with AML and MDS. We believe that JSP191 has the potential to significantly improve transplantation for patients ineligible for intensive myeloablative conditioning, and are hopeful that this study will be a major step forward...